Science

Jan 30, 2025, 08:44

Final analysis of the PRECIOUS phase 3 trial

Paolo Tarantino, Clinical Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared an article by Yutaka Yamamoto, et al. on X:

“Final analysis of the PRECIOUS phase 3 trial out in Journal of Clinical Oncology.

Despite yielding only a small PFS advantage, pertuzumab rechallenge in HER2+ MBC led to a relevant OS benefit (Δ 10 mo). Could become actionable if T-DXd/pertuzumab make it to the first line.”

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.

Authors: Yutaka Yamamoto, et al.

Final analysis of the PRECIOUS phase 3 trial

cancer Dana-Farber Cancer Institute fight against cancer Global fight against cancer Harvard Medical School Journal of Clinical Oncology metastatic breast cancer OncoDaily Oncology Paolo Tarantino pertuzumab Yutaka Yamamoto

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer